期刊
INTERNATIONAL JOURNAL OF CANCER
卷 148, 期 11, 页码 2652-2663出版社
WILEY
DOI: 10.1002/ijc.33451
关键词
age; age acceleration; biological age; cancer; DNA methylation; epigenetic
类别
资金
- UKRI Future Leaders Fellowship [MR/S03532X/1]
- MRC [MR/M501669/1] Funding Source: UKRI
- UKRI [MR/S03532X/1] Funding Source: UKRI
Cancer is known to be associated with aging, with declines in DNA repair and epigenetic maintenance mechanisms potentially contributing to cancer development. DNA methylation levels, as assessed through epigenetic clocks, are promising markers for predicting cancer risk and mortality. Further research on biological age biomarkers is likely to provide more insights into the connections between aging and cancer.
Cancer is well established as an age-associated disease, and there is substantial overlap in the molecular, cellular and physiological changes observed with both ageing and the progression of cancer. Age-specific declines in resilience mechanisms such as DNA repair or epigenetic maintenance may contribute to the development of cancer. These declines may be assessed through biomarkers that measure biological age and through the related concept of age acceleration. Epigenetic clocks, assessed through DNA methylation levels, are among the most widely used biological age markers in cancer studies. In this review, we discuss the use of DNA methylation ageing measures to predict population cancer incidence, mortality and survival. Blood-based DNA methylation age estimators appear to be promising measures of increased cancer risk and mortality, although their reported effects are generally weak, thus its clinical relevance remains to be validated in large case-cohort and longitudinal studies. Future development of epigenetic and other biological age biomarkers will likely further elucidate the links between ageing and cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据